GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>…the time for DNA/BIIB's [CD20] product to become generic is not that long.<

I do not understand why you say this. In the U.S., the patents of greatest consequence for a second-generation humanized mAb have not even issued yet. Here’s an excerpt from BIIB’s latest 10K report:

http://www.sec.gov/Archives/edgar/data/875045/000095013507000981/b63632bie10vk.htm

>>
Our recently-granted patent in certain European countries claiming the treatment with anti-CD-20 antibodies of certain auto-immune indications, including rheumatoid arthritis, has been opposed by numerous third parties. This opposition proceeding is likely to be protracted and its outcome is uncertain at this time.

…In addition, we and our collaborator, Genentech, have filed numerous patent applications directed to anti-CD-20 antibodies and their uses to treat various diseases. These pending patent applications have the potential of issuing as patents in the U.S. and abroad covering anti-CD-20 antibody molecules for periods beyond that stated above for RITUXAN and ZEVALIN.
<<

Regards, Dew